Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors
AssigneeImmunityBio, Inc.
InventorsJohn H. Lee, Laurent H. Boissel, Hans G. Klingemann
Life of this patent
Estimating the term…
Loading patent…
AssigneeImmunityBio, Inc.
InventorsJohn H. Lee, Laurent H. Boissel, Hans G. Klingemann
Estimating the term…
Provided are genetically modified NK cells expressing a chimeric antigen receptor targeting an EGFR superfamily receptor. The CAR can comprise an intracellular domain of FcεRIγ and further recombinant proteins expressed by the genetically modified NK cells are CD16, autocrine growth stimulating cytokines, and optionally one of IL-12, a TGF-beta trap, or a homing receptor. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient the genetically modified NK cells.
A genetically modified NK cell comprising one or more recombinant nucleic acids encoding and expressing
Dependencies are inferred from the claim text.